Gene Delivery Using Chemical Methods - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 192

[157] Peracchia MT, Vauthier C, Puisieux F, Couvreur P. Development of sterically stabilized
poly (isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly (ethylene
glycol). J Biomed Mater Res 1997;34:317-26.
[158] Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaele D,
et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycya-
noacrylate nanoparticles. Biomaterials 1999;20:1269-75.
[159] Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, et al. Stealth
PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic
targeting. J Control Release 1999;60:121-8.
[160] Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al.
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor thera-
peutic efficacy. Proc Natl Acad Sci USA 1991;88:11460-4.
[161] Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circula-
tion time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;
85:6949-53.
[162] Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, Mouton JW, Woodle MC, Storm
G. Liposomes with prolonged blood circulation and selective localization in Klebsiella
pneumoniae -infected lung tissue. J Infect Dis 1993;168:164-71.
[163] Stella B, Arpicco S, Peracchia MT, Desmaele D, Hoebeke J, Renoir M, et al. Design of
folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 2000;89:1452-64.
[164] Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacryl
ate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery
of oligonucleotides. Pharm Res 2000;17:707-14.
[165] Godard G, Boutorine AS, Saison-Behmoaras E, Helene C. Antisense effects of cho-
lesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate)
nanoparticles. Eur J Biochem 1995;232:404-10.
[166] Balland O, Saison-Behmoaras T, Garestier T. Nanoparticles as carriers for antisense oli-
gonucleotides. In: McCormack B, editor. Targeting of drugs 5: strategies for oligonucle-
otide and gene delivery in therapy. New York, NY: Plenum Press; 1996. p. 131-42.
[167] Zobel HP, Kreuter J, Werner D, Noe CR, Kumel G, Zimmer A. Cationic polyhexylcya-
noacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic
Acid Drug Dev 1997;7:483-93.
[168] Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C, et al. Antisense oli-
gonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit
mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl
Acad Sci USA 1994;91:10460-4.
[169] Schwab G, Duroux L, Chavany C, Helene C, Saison-Behmoaras E. An approach for
new anticancer drugs: oncogene-targeted antisense DNA. Ann Oncol 1994;5:S55-8.
[170] Nakada Y, Fattal E, Foulquier M, Couvreur P. Pharmacokinetics and biodistribution of
oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intrave-
nous administration in mice. Pharm Res 1996;13:38-43.
[171] Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, et al. EWS
fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem
Biophys Res Commun 2000;279:401-6.
[172] Mumper RJ, Duguid JG, Anwer K, Barron MK, Nitta H, Rolland AP. Polyvinyl deriva-
tives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res
1996;13:701-9.
[173] Mumper RJ, Rolland AP. Plasmid delivery to muscle: recent advances in polymer deliv-
ery systems. Adv Drug Del Rev 1998;30:151-72.